Watch KPTIQ. Know when insiders buy.
One email the day a filing lands. Free.
KPTIQ
Karyopharm Therapeutics Inc.
0.03
−0.00 −3.85%
USD · close Nov 13
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $567KP/E —DIV YIELD —FCF YIELD —REV TTM $146.6M +6.8%NET INCOME −$224.7MNET DEBT $114.3M52W 0.02 – 0.11SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $33.4M | −11.9% | — | −$22.5M | −$67M | — | -2.32 | −$24.9M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $35.1M | +16.8% | — | −$26.8M | −$22.4M | — | -1.24 | −$22.7M | — | — | May 14 |
| Q4 2025 · Dec 31derived | $34.1M | +11.6% | — | −$17.8M | −$102.2M | — | -7.00 | −$11.8M | $0 | −$11.8M | Feb 13 |
| Q3 2025 · Sep 30 | $44M | +13.6% | — | −$15.2M | −$33.1M | — | -3.82 | −$5.9M | $0 | −$5.9M | Nov 3 |
| Q2 2025 · Jun 30 | $37.9M | −11.4% | — | −$24.4M | −$37.3M | −256.6% | -4.32 | −$18.7M | $0 | −$18.7M | Aug 13 |
| Q1 2025 · Mar 31 | $30M | −9.4% | — | −$33.3M | −$23.5M | — | -2.77 | −$39M | $0 | −$39M | May 14 |
| Q4 2024 · Dec 31derived | $30.5M | −9.5% | — | −$31.3M | −$30.8M | — | -3.60 | −$25.8M | −$53K | −$25.8M | Feb 13 |
| Q3 2024 · Sep 30 | $38.8M | +7.7% | — | −$26.3M | −$32.1M | — | -3.85 | −$19.5M | $0 | −$19.5M | Nov 3 |
| Q2 2024 · Jun 30 | $42.8M | — | — | −$28.1M | $23.8M | — | -2.97 | −$38.5M | $0 | −$38.5M | Aug 11 |
| Q1 2024 · Mar 31 | $33.1M | — | — | −$33.8M | −$37.4M | — | -4.85 | −$43.7M | $195K | −$43.9M | May 12 |
| Q4 2023 · Dec 31derived | $33.7M | — | — | −$37.8M | −$41.8M | — | -17.90 | −$18.6M | $0 | −$18.6M | Feb 13 |
| Q3 2023 · Sep 30 | $36M | — | — | −$31.3M | −$34.5M | — | -0.30 | −$29.5M | $0 | −$29.5M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $146.1M | — | −$90.7M | −$196M | -134.2% | -17.93 | −$75.4M | $0 | −$75.4M | — | — |
| FY2024 · to Dec 31 | $145.2M | — | −$119.4M | −$76.4M | -52.6% | -14.00 | −$127.5M | $142K | −$127.6M | — | — |
| FY2023 · to Dec 31 | $146M | — | −$129.5M | −$143.1M | -98.0% | -18.79 | −$92.7M | $0 | −$92.7M | — | — |
| FY2022 · to Dec 31 | $157.1M | — | −$142.2M | −$165.3M | -105.2% | -2.02 | −$149.6M | $118K | −$149.7M | — | — |
| FY2021 · to Dec 31 | $209.8M | — | −$98.3M | −$124.1M | -59.1% | -1.65 | −$107.1M | $212K | −$107.3M | — | — |
| FY2020 · to Dec 31 | $108.1M | — | −$171.8M | −$196.3M | -181.6% | -2.72 | −$160.2M | $145K | −$160.4M | — | — |
Every number comes from Karyopharm Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.